Genetic analysis suggests high misassignment rates in clinical Alzheimer's cases and controls
V. Escott-Price, E. Baker, M. Shoai, G. Leonenko, A.J. Myers, M. Huentelman, J. Hardy
Through comparisons of genetics analyses of clinical case control studies with pathological case control studies of Alzheimer’s disease, this publication demonstrates that, at typical ages for case control studies (70-80 years), about 30% on clinically assigned controls are likely to be in the early stages of disease. This would suggest that Biomarker studies would need to take this into account when carrying out future case control comparisons.